| Id: | acc4654 |
| Group: | 1sens |
| Protein: | JNK |
| Gene Symbol: | Mapk8 |
| Protein Id: | P49185 |
| Protein Name: | MK08_RAT |
| PTM: | phosphorylation |
| Site: | Thr183 |
| Site Sequence: | RTAGTSFMMTPYVVTRYYRAP |
| Disease Category: | Nervous system diseases |
| Disease: | Depression |
| Disease Subtype: | LPS induced |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | SP600125 |
| Drug Info: | "SP600125 is a well - known drug, often used as a specific inhibitor of c - Jun N - terminal kinase (JNK). " |
| Effect: | modulate |
| Effect Info: | "LPS injection induces depression-like behaviors, accompanied by increased expression of inflammatory cytokines, enhanced JNK activation, and elevated phosphorylation levels of glucocorticoid receptor (GR) at serine 246 in the parahippocampal gyrus (Hb), amygdala (Amyg), and medial prefrontal cortex (mPFC). The JNK inhibitor SP600125 can alleviate these effects." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 31901732 |
| Sentence Index: | 31901732_6 |
| Sentence: | "The results showed that LPS infusion led to depressive-like behaviors, accompanied by increased proinflammatory cytokine expression, increased JNK activation, and upregulated glucocorticoid receptor (GR) phosphorylation at serine 246 (pGR-Ser246) in the habenula (Hb), amygdala (Amyg) and medial prefrontal cortex (mPFC)." |
Sequence & Structure:
MSRSKRDNNFYSVEIADSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCLKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSKMLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEVMDLEERTKNGVIRGQPSPLGAAVINGSQHPVSSPSVNDMSSMSTDPTLASD
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 183 | D | Alzheimer's disease | Phosphorylation | 23474850 |
| T | 183 | D | Short-term oestrogen deprivation | Phosphorylation | 23474850 |
| T | 183 | U | Alzheimer's disease | Phosphorylation | 23474850 |
| T | 183 | U | Short-term oestrogen deprivation | Phosphorylation | 23474850 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
